newsfilter
← Earnings
Earnings Releases·

Jasper Therapeutics — Third Quarter 2026 Earnings Summary

Jasper Therapeutics reported third-quarter 2026 financial results showing $135.3 million in cash and cash equivalents alongside a net loss of $144.5 million for the quarter. The company advanced its clinical pipeline by completing enrollment in the first cohort of a Phase 2 renal basket study for vensobafusp alfa in IgA nephropathy and initiating enrollment for patients with IC-MPGN. Recent corporate developments include the July 2026 acquisition of Kira Pharmaceuticals, a $132 million private placement, and a 1-for-30 reverse stock split effected in November 2026.

Company
JASPER THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology